Healthcare & Medical Devices Global On demand · 24-48h

Global Luciferase Market Strategic Research Report

Global Luciferase Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Luciferase Market
$1B2025
6.7%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Luciferase Assay Kits, Recombinant Luciferase, Reporter Gene Vectors/Cell Lines, Others

By Application: Hospitals & Clinics, Research Institutes, Pharmaceutical Companies, Testing Laboratories, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Promega, Thermo Fisher Scientific, Merck KGaA, Revvity, Takara Bio, New England Biolabs, Biotium, BPS Bioscience, Abcam, OriGene Technologies, Gold Biotechnology, Bio-Techne, Cell Signaling Technology, Creative Diagnostics, Vazyme, Yeasen Biotechnology, Beyotime Biotechnology, TransGen Biotech, Genomeditech

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 127 pages
Market size 2025
$1B
Billion USD
Forecast CAGR
6.7%
2025-2032
Forecast 2032
$1.6B
Projected
区域
5
Asia Pacific · Latin America · MEA · Europe · North America

概述

Scope of the Report

The global Luciferase market size is predicted to grow from US$ 1,001 million in 2025 to US$ 1,587 million in 2032; it is expected to grow at a CAGR of 6.7% from 2026 to 2032.

Global sales volume of luciferase reached 1,185 thousand units in 2025, with an average price of $86.35 per unit.

Luciferase is a general term for a class of enzymes found in living organisms that catalyze the oxidation of luciferin or fatty aldehydes to produce light. Luciferases are widely distributed among bioluminescent organisms in nature, such as fireflies and luminous bacteria. Based on differences in origin and structure, luciferases can be categorized into three main types: firefly luciferase, bacterial luciferase, and marine organism luciferase.

Its core function involves catalyzing a chemical reaction between the substrate (luciferin) and oxygen, converting chemical energy into light energy to produce bioluminescence that is visible to the naked eye or detectable by instruments. The light-emitting process requires no external excitation source; light is produced autonomously through the enzymatic reaction. Characterized by high specificity and sensitivity, luciferase serves as a highly valuable tool molecule in life science research.

Luciferase is not a bulk industrial enzyme; it is primarily marketed in forms such as recombinant luciferase, luciferase assay kits, dual-luciferase reporter gene systems, and ATP/cell viability bioluminescence assay reagents.

Global key Luciferase players cover Promega, Thermo Fisher Scientific, Merck KGaA, Revvity, Takara Bio, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Luciferase market?

What factors are driving Luciferase market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Luciferase market opportunities vary by end market size?

How does Luciferase break out by Type, by Application?

This report presents a comprehensive overview of the global Luciferase market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Luciferase Assay Kits
  • Recombinant Luciferase
  • Reporter Gene Vectors/Cell Lines
  • Others

Segment by Enzyme Type

  • Firefly Luciferase
  • Bacterial Luciferase
  • Marine Luciferase
  • Others

Segment by Assay System

  • Single-Luciferase Assay
  • Dual-Luciferase Assay
  • Others

Segment by Application

  • Hospitals & Clinics
  • Research Institutes
  • Pharmaceutical Companies
  • Testing Laboratories
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Luciferase market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospitals & Clinics, Research Institutes, Pharmaceutical Companies evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Luciferase Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6.7%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1B
2025
Forecast
$1.6B
2032
CAGR
6.7%
2025–2032
区域
5
global
Key companies
PromegaThermo Fisher ScientificMerck KGaARevvityTakara BioNew England BiolabsBiotiumBPS Bioscience
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Luciferase Assay KitsRecombinant LuciferaseReporter Gene Vectors/Cell LinesOthers
By Application
Hospitals & ClinicsResearch InstitutesPharmaceutical CompaniesTesting LaboratoriesOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Luciferase Assay Kits
  • 3.1.3 Recombinant Luciferase
  • 3.1.4 Reporter Gene Vectors/Cell Lines
  • 3.1.5 Others
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospitals & Clinics
  • 4.1.3 Research Institutes
  • 4.1.4 Pharmaceutical Companies
  • 4.1.5 Testing Laboratories
  • 4.1.6 Others
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Promega
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Thermo Fisher Scientific
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Merck KGaA
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Revvity
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Takara Bio
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 New England Biolabs
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Biotium
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 BPS Bioscience
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Abcam
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 OriGene Technologies
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Gold Biotechnology
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Bio-Techne
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Cell Signaling Technology
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Creative Diagnostics
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Vazyme
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Yeasen Biotechnology
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Beyotime Biotechnology
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 TransGen Biotech
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Genomeditech
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Luciferase market?
The global Luciferase market is estimated at US$ 1 billion in 2025 (base year) and is projected to reach US$ 1.59 billion by 2032.
How fast is the Luciferase market expected to grow?
The market is expected to grow at a CAGR of 6.7% from 2026 to 2032, expanding from US$ 1 billion in 2025 to US$ 1.59 billion in 2032, roughly 1.6 times its base-year value.
What does the Luciferase market cover?
Global sales volume of luciferase reached 1,185 thousand units in 2025, with an average price of $86.35 per unit.
How is the Luciferase market segmented by type?
By type, the market is segmented into Luciferase Assay Kits, Recombinant Luciferase, Reporter Gene Vectors/Cell Lines and Others.
What are the key applications of Luciferase?
Key applications covered include Hospitals & Clinics, Research Institutes, Pharmaceutical Companies, Testing Laboratories and Others.
Which companies are profiled in the Luciferase market report?
Key players profiled include Promega, Thermo Fisher Scientific, Merck KGaA, Revvity, Takara Bio, New England Biolabs, Biotium and BPS Bioscience, among 19 companies covered in total.
What geographies does the Luciferase market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Luciferase?
What factors are driving Luciferase market growth, globally and by region?
Who should buy the Luciferase market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospitals & Clinics, Research Institutes and Pharmaceutical Companies, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Luciferase market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.